Dearborn Partners LLC Has $1.17 Million Stake in Pfizer Inc. (NYSE:PFE)

Dearborn Partners LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 7.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 40,260 shares of the biopharmaceutical company’s stock after buying an additional 2,938 shares during the quarter. Dearborn Partners LLC’s holdings in Pfizer were worth $1,165,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Marshall Wace LLP raised its position in shares of Pfizer by 279.3% during the second quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock worth $150,481,000 after purchasing an additional 8,378,173 shares during the period. Swedbank AB bought a new stake in shares of Pfizer during the 1st quarter worth $172,902,000. International Assets Investment Management LLC bought a new position in shares of Pfizer during the 3rd quarter valued at approximately $146,481,000. 1832 Asset Management L.P. increased its position in Pfizer by 24,961.6% in the second quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock worth $69,891,000 after buying an additional 2,487,919 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its stake in Pfizer by 120.7% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 4,498,313 shares of the biopharmaceutical company’s stock valued at $130,181,000 after acquiring an additional 2,459,666 shares during the period. Institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by insiders.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Finally, Wells Fargo & Company raised their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, five have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Trading Down 2.6 %

Shares of NYSE:PFE opened at $26.02 on Friday. The firm has a market capitalization of $147.46 billion, a price-to-earnings ratio of 35.16, a price-to-earnings-growth ratio of 0.85 and a beta of 0.67. The business’s 50 day moving average price is $28.76 and its 200-day moving average price is $28.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period in the previous year, the business posted ($0.17) EPS. Pfizer’s revenue was up 31.2% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.46%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.